On Target Laboratories discovers and develops fluorescent markers to target and illuminate cancer during surgery.
Our technology reduces the uncertainty associated with finding and removing diseased tissue during medical procedures, empowering surgeons to provide a more precise and complete surgical resection.
Our technology is based on the pioneering work of Philip S. Low, PhD, the Ralph C. Corley Distinguished Professor of Chemistry at Purdue University and Director of the Purdue University Center for Drug Discovery.
Chris Barys is the President and Chief Executive Officer of ON TARGET LABORATORIES. He has been a Business Leader and Medical Device Executive for 27 years. Chris is an inspirational leader who aligns organizations around a common vision while keeping the team laser focused on the priorities that fuel growth. His expertise is in channel innovation and market access. As Senior Vice President for Philips Image Guided Therapy, Chris was responsible for uniting Philips’ imaging and device businesses in order to solve some very real, complex, and technical challenges that exist in healthcare today. His mission was to align the IGT Devices organization around a singular vision to better treat patients by helping physicians decide, guide, treat and confirm the right therapy for each patient in real time. This unique algorithm allowed clinicians to improve workflow, improve clinical outcomes while reducing the cost of care. During his tenure at Philips, Chris was responsible for 3 major acquisitions that built significant value for Philips shareholders. Chris’ 27 years of medical device experience is hallmarked by introducing many new technologies to the market including several combination drug-device innovations. As a seasoned executive, he has proven experience in developing markets and building channels that can deliver consistent growth. He is fueled by the fundamental desire to transform care and improve outcomes for patients around the world, with innovation at the forefront of all work. Prior to joining Philips in 2016, Chris served as Vice President and General Manager of the Interventional Lung Solutions (ILS) division of Early Technologies at Medtronic, growing the business to become the global leader of interventional lung solutions for the management of lung diseases. Previously, Chris held various senior leadership positions at FlowCardia, Edwards LifeSciences, Johnson and Johnson, Boston Scientific and United States Surgical Corporation. Chris earned his Bachelor of Science degree in Marketing from Northern Illinois University in DeKalb, Illinois.
Tim Biro, RPh is the Chief Operating Officer of ON TARGET LABORATORIES. Tim has entrepreneurial experience in the medical device and pharmaceutical industry having served as the Co-Founder and CEO of several companies including SpineMatrix and Therox Pharmaceuticals, and the CEO of OncoImmune. He also has extensive experience in venture capital, as the Founder and Managing Partner of Ohio Innovation Fund, and a Partner in Reservoir Venture Partners and Brantley Venture Partners. Prior to his career in venture capital, Tim held various management positions with Merck. Tim holds a BS in Microbiology from Pennsylvania State University, a BS in Pharmacy from Temple University, an MBA in Finance and Marketing from the Wharton School of Business, and is a Fellow of Temple University.
Philip Low, PhD is the Chief Science Officer and a Founder of ON TARGET LABORATORIES. Phil has served on the faculty at Purdue University since August 1976, where he is currently the Ralph C. Corley Distinguished Professor of Chemistry and Presidential Scholar for Drug Discovery. He has published more than 425 scientific articles with a collective H-index >100 and has received numerous national and international awards including an NIH MERIT Award, the AACR’s Award for Chemistry in Cancer Research, and the American Chemical Society’s Award for Cancer Research. Phil has more than 75 active/pending US patents and was elected to the National Academy of Inventors. To commercialize his discoveries, he has founded 6 successful biotech companies. Phil holds a BS in Chemistry from Brigham Young University and a PhD in Biochemistry from the University of California San Diego.
Sumith Kularante, PhD is the Executive Vice President of Research and Development at ON TARGET LABORATORIES. His scientific efforts have resulted in 6 drug candidates in human clinical trials, >50 patents, and >50 peer-reviewed publications. Sumith has received numerous national and international awards including SBIR Phase II Grant Award & Phase I for lung cancer research, AAPS Postdoctoral Fellow Award sponsored by Merck for CXCR4-targeted ADC for metastatic cancers, the Skaggs Postdoctoral Fellow Award, and AAPS Graduate Student Award in Biotechnology, sponsored by Pfizer & AAPS Graduate Student Symposium Award sponsored by Eli Lilly for PSMA-targeted drugs for prostate cancer. After graduating with a PhD in chemistry from Purdue University conducting research with Prof. Philip Low, Sumith pursued his postdoctoral studies in molecular biology with Prof. Peter G. Schultz at The Scripps Research Institute, San Diego.
Kathleen Ward, CPA is the Vice President of Finance at ON TARGET LABORATORIES. Kathy Ward was most recently Chief Financial Officer at Tru-Flex, a global manufacturing company, where she was responsible for overseeing the accounting, finance and reporting functions worldwide. She has more than 20 years of experience in financial planning, analysis and compliance to support growth and foundational financial responsibilities. Kathy has a BS in Finance and Accounting from Indiana University, is an Ernst & Young CPA and holds an MBA from Ball State University.
Ben Lundgren is the Vice President of Marketing and Commercialization at ON TARGET LABORATORIES. Ben has extensive experience in both the pharmaceutical and medical device industries. Most recently he held various leadership roles over 12 years in pharmaceutical and medical device strategic marketing and commercial execution within Johnson & Johnson, across both Janssen Pharmaceuticals and Ethicon. Prior to joining Johnson & Johnson, Ben worked at Bain & Company, where he served clients in a diverse set of industries in the United States, Latin America, and Europe. Ben received a BS in Accounting from Brigham Young University and holds an MBA in Marketing and Finance from the Wharton School of Business.
Kimberly Fabrizio is Vice President of Regulatory Affairs and Quality Assurance at ON TARGET LABORATORIES. Kimberly has 20+ years’ experience holding various regulatory affairs and quality assurance leadership roles in small to large pharmaceutical development organizations including Bayer, Forest Labs, and Invicro. She has successfully brought over 75 novel compounds into human investigation. In addition, Kimberly has led over 10 NDA/sNDA teams to successful approval of drugs in various therapeutic areas including oncology, anti-infective, and psychiatry. She has successfully hosted 4 FDA inspections at several companies in her Quality role. Kimberly holds a BA in Mass Communications from Quinnipiac University in Hamden, Connecticut.
Fritz French was a co-founder and CEO of Calibrium, a start-up biopharmaceutical company focused on developing therapeutics for the treatment of diabetes and obesity. Calibrium was sold to Novo Nordisk at the end of 2015. Previously, he was CEO of Marcadia Biotech, another startup biopharmaceutical company in the diabetes and obesity area, from company inception until just after sale to Roche in 2010. Prior to Marcadia, Fritz was Vice President, Global Marketing for the Vascular Intervention division (now part of Abbott) of Guidant Corporation (acquired by Boston Scientific) and immediately prior to this, he held the role of Vice President, Corporate Marketing and Communications. Fritz also served as President and CEO of two life science start-up companies, Corvascular, Inc. and Zephyr Medical. He had previously worked at Guidant and the Medical Devices and Diagnostic Division of Lilly, serving in numerous marketing, sales, and general management positions for Lilly and Guidant, both in the U.S. and Europe. Fritz currently serves on the board of directors of FAST BioMedical, On Target Laboratories, and Anagin. Fritz earned a B.S. from the Kelley School of Business, Indiana University, and an M.B.A. from Harvard Business School, Harvard University.
V. Kadir Kadhiresan, PhD, Vice President, Venture Investments, with Johnson & Johnson Innovation – JJDC, Inc. (JJDC). Kadir has more than a decade of operational experience in various functional roles including research, product development, and business development. Prior to entering business development, he led the research and development of multiple early-stage technologies and products in cardiac rhythm management and heart failure. He is an inventor on more than 40 patents and has published several articles in peer-reviewed journals. Kadir received a PhD and Master of Science in Biomedical Engineering from the University of Michigan, Ann Arbor, a Master of Business Administration from the Kellogg School of Management at Northwestern University, and a Bachelor of Science in Electrical Engineering from National Institute of Technology (REC), Trichy, India.
David Stone is the Vice President and Chief Investment Officer for the Pension Fund of the Christian Church Indianapolis. He is a Board Member for On Target Laboratories since 2014. David has an MBA from Michigan State University.
As a Managing Director at H.I.G. BioHealth Partners, Michael Wasserman focuses on investment opportunities in the life sciences sector, including biopharmaceuticals and medical devices. Michael currently represents H.I.G. Capital on the boards of: Orbus Therapeutics, VertiFlex, Leiter’s Pharmacy and On Target Labs. He also led H.I.G.’s investment in NeuWave Medical, prior to its acquisition by Johnson & Johnson and HyperBranch Medical Technology, which was acquired by Stryker. Prior to joining H.I.G., Michael was with Innovations Foundation, where he focused on the creation, financing and development of high technology companies in the life sciences, information technology and engineering sectors. At Innovations Foundation, Michael was instrumental in building multiple high growth companies derived from academic or federally sponsored research programs. Michael has also held prominent operating roles in several entrepreneurial and venture-backed life sciences efforts. Michael was a Founder of CELLutions Biosystems (acquired by Cedarlane Laboratories), where he broadly managed business operations and was directly responsible for the successful negotiation of partnership, co-development and licensing agreements with industry leading pharmaceutical and biotechnology organizations. Michael also has extensive clinical research experience. As Director of Research at Advanced Therapeutics, Michael was involved in a series of seminal clinical studies involving biological approaches to treat rheumatoid arthritis and other autoimmune and inflammatory disorders. Earlier in his career, Michael worked directly for, or as a consultant to, several early stage life sciences businesses, and in the corporate finance, pharmaceutical and clinical research industries. Michael received his B.Sc. from McGill University and his Ph.D. in Pharmacology from the University of Toronto.
Bernie Haffey is President of Haffey&Co., a management consulting firm that has helped over twenty helps organizations achieve world-class customer, employee and shareholder results. Previously he served as President and CEO of two successful venture-backed start-ups: Nexis Vision, Inc., and NDO Surgical, Inc.
Mr. Haffey also served as Executive Vice President and Chief Commercial Officer at Summit Technology, Inc., and Executive Vice President and Chief Commercial Officer at IntraLase Corp, start-ups that acheived $>100M in revenue and ~ $1B exits under his management. Earlier in his career he held executive management positions at Mentor Corp and in Hewlett Packard Company’s Medical Products Group.
Mr. Haffey earned a BA from Colgate University and an MBA from Cornell University.